









市场行情
/
股票
/
nasdaq-tgtx
/

TG Therapeutics Inc

TGTX

29.230USD

-5.790-16.53%

交易中（美东）报价延迟15分钟

4.62B总市值

118.09市盈率 TTM



TG Therapeutics Inc

29.230

-5.790-16.53%

概览公司财务

TG Therapeutics, Inc. 是一家完全整合的商业阶段生物制药公司。该公司专注于收购、开发和商业化 B 细胞疾病的新型治疗方法。其临床候选药物包括 Ublituximab（抗 CD20 mAb）、TG-1701（BTK 抑制剂）和 TG-1801（抗 CD47/CD19 双特异性 mAb）。BRIUMVI 是一种抗 CD20 单克隆抗体，用于治疗 RMS，包括临床孤立综合征、复发缓解性疾病和活动性继发进展性疾病。TG-1701 是一种新型口服共价结合的布鲁顿酪氨酸激酶 (BTK) 抑制剂，在体外激酶筛选中表现出对 BTK 的选择性。TG-1801 是一种双特异性 CD47 和 CD19 抗体。这是一种针对 CD19（一种在 B 细胞恶性肿瘤中表达的 B 细胞特异性市场）和 CD47 的疗法。它还评估互补产品、技术和公司，以寻找许可、合作、收购和/或投资机会。

公司简介

公司代码TGTX

公司名称TG Therapeutics Inc

上市日期Dec 14, 1995

CEOMr. Michael S. Weiss, J.D.

员工数量338

证券类型Ordinary Share

年结日Dec 14

公司地址3020 Carrington Mill Blvd., Suite 475

城市MORRISVILLE

上市交易所NASDAQ Capital Market Consolidated

国家United States of America

邮编27560-5435

电话18775758489

网址https://www.tgtherapeutics.com/

公司代码TGTX

上市日期Dec 14, 1995

CEOMr. Michael S. Weiss, J.D.

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Michael S. Weiss, J.D.

Chairman of the Board, President, Chief Executive Officer

13.82M

Mr. Sean A. Power

Chief Financial Officer, Treasurer, Corporate Secretary

600.61K

-19.72%

Mr. Kenneth (Ken) Hoberman

Independent Director

279.65K

+5.56%

Dr. Yann Echelard

Independent Director

228.82K

+2.11%

Mr. Laurence Neil (Larry) Charney, CPA

Lead Independent Director

222.89K

+10.63%

Mr. Daniel Hume, J.D.

Independent Director

192.75K

+8.27%

Dr. Sagar Lonial

Independent Director

114.91K

+14.69%

名称

名称/职务

职务

持股

持股变动

Mr. Michael S. Weiss, J.D.

Chairman of the Board, President, Chief Executive Officer

13.82M

Mr. Sean A. Power

Chief Financial Officer, Treasurer, Corporate Secretary

600.61K

-19.72%

Mr. Kenneth (Ken) Hoberman

Independent Director

279.65K

+5.56%

Dr. Yann Echelard

Independent Director

228.82K

+2.11%

Mr. Laurence Neil (Larry) Charney, CPA

Lead Independent Director

222.89K

+10.63%

Mr. Daniel Hume, J.D.

Independent Director

192.75K

+8.27%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

业务USD

名称

营收

占比

Total product revenue, net

119.66M

99.01%

Royalty Revenue

605.00K

0.50%

Other Revenue

558.00K

0.46%

License Revenue

38.00K

0.03%

Milestone Revenue

0.00

0.00%

暂无数据

业务

地区

业务USD

名称

营收

占比

Total product revenue, net

119.66M

99.01%

Royalty Revenue

605.00K

0.50%

Other Revenue

558.00K

0.46%

License Revenue

38.00K

0.03%

Milestone Revenue

0.00

0.00%

股东统计

更新时间: 5月16日周五

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

12.11%

The Vanguard Group, Inc.

9.81%

Weiss (Michael S)

8.71%

State Street Global Advisors (US)

4.68%

Geode Capital Management, L.L.C.

2.07%

Other

62.63%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

12.11%

The Vanguard Group, Inc.

9.81%

Weiss (Michael S)

8.71%

State Street Global Advisors (US)

4.68%

Geode Capital Management, L.L.C.

2.07%

Other

62.63%

股东类型

持股股东

占比

Investment Advisor

35.59%

Investment Advisor/Hedge Fund

16.95%

Individual Investor

9.74%

Hedge Fund

4.94%

Research Firm

3.73%

Pension Fund

1.23%

Bank and Trust

0.41%

Sovereign Wealth Fund

0.25%

Family Office

0.13%

Other

27.03%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

691

115.81M

72.94%

-20.80M

2025Q1

704

116.82M

73.80%

-25.76M

2024Q4

657

113.87M

72.65%

-36.14M

2024Q3

598

117.83M

76.11%

-20.28M

2024Q2

544

109.58M

70.90%

-28.91M

2024Q1

535

105.41M

68.45%

-29.01M

2023Q4

542

104.64M

69.13%

-36.73M

2023Q3

552

104.67M

69.33%

-30.54M

2023Q2

543

102.45M

68.58%

-35.33M

2023Q1

550

108.72M

74.29%

-22.90M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

19.22M

12.11%

-465.28K

-2.36%

Mar 31, 2025

The Vanguard Group, Inc.

15.57M

9.81%

+8.03K

+0.05%

Mar 31, 2025

Weiss (Michael S)

13.82M

8.71%

Apr 14, 2025

State Street Global Advisors (US)

7.43M

4.68%

-1.77M

-19.20%

Mar 31, 2025

Geode Capital Management, L.L.C.

3.28M

2.07%

+89.06K

+2.79%

Mar 31, 2025

Soleus Capital Management, L.P.

2.85M

1.79%

+165.46K

+6.17%

Mar 31, 2025

ClearBridge Investments, LLC

2.64M

1.67%

+809.33K

+44.10%

Mar 31, 2025

Pictet Asset Management Ltd.

2.40M

1.51%

-396.75K

-14.20%

Mar 31, 2025

Fidelity Management & Research Company LLC

1.74M

1.1%

+710.43K

+68.88%

Mar 31, 2025

Hood River Capital Management LLC

1.56M

0.98%

+101.17K

+6.95%

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

Invesco S&P SmallCap Health Care ETF

3.49%

Invesco Biotechnology & Genome ETF

2.71%

Virtus LifeSci Biotech Products ETF

1.86%

SPDR S&P Biotech ETF

1.72%

Invesco S&P SmallCap 600 Pure Growth ETF

1.69%

Direxion Daily S&P Biotech Bull 3X Shares

0.98%

Invesco S&P SmallCap Momentum ETF

0.95%

SPDR S&P 600 Small Cap Growth ETF

0.71%

Vanguard S&P Small-Cap 600 Growth Index Fund

0.71%

First Trust NASDAQ Pharmaceuticals ETF

0.67%

Invesco S&P SmallCap Health Care ETF

占比3.49%

Invesco Biotechnology & Genome ETF

占比2.71%

Virtus LifeSci Biotech Products ETF

占比1.86%

SPDR S&P Biotech ETF

占比1.72%

Invesco S&P SmallCap 600 Pure Growth ETF

占比1.69%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.98%

Invesco S&P SmallCap Momentum ETF

占比0.95%

SPDR S&P 600 Small Cap Growth ETF

占比0.71%

Vanguard S&P Small-Cap 600 Growth Index Fund

占比0.71%

First Trust NASDAQ Pharmaceuticals ETF

占比0.67%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

KeyAI

